Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer

Abstract

Background and objectives: Hypertherm intraperitoneal chemotherapy (HIPEC) is increasingly used in the treatment of ovarian, tubal, and primary peritoneal cancer (OC). The aim was to evaluate short‐term morbidity of cytoreductive surgery (CRS) and carboplatin HIPEC. Methods: Prospective feasibility study performed from January 2016 to December 2017. Twenty‐five patients with primary OC (FIGO III‐IV) received upfront or interval CRS combined with carboplatin HIPEC at dose 800 mg/m 2. Primary outcome measurements: grade 3 to 5 adverse events within 30 days according to Common Terminology Criteria for Adverse Events. Secondary outcome measurements: reoperation rate, length of hospital stay, readmission rate, and time from surgery to systemic chemotherapy administration. Results: No deaths (grade 5) or grade 4 adverse events were observed. Eleven patients (44.0%) experienced at least one grade 3 adverse event, the most common being an infection (28.0%) and neutropenia (12.0%). The reoperation rate was 8.0%. The median hospital stay was 14 days (range 9‐25 days), and five patients (25.0%) were readmitted within 30 days after surgery. Median time from surgery to the administration of the first dose of systemic chemotherapy was 41 days (range 24‐81 days). Conclusion: Our small‐scale prospective study supports that CRS and carboplatin HIPEC used for primary advanced‐stage OC is feasible with acceptable morbidity.

Cancer follow-up supported by patient-reported outcomes in patients undergoing intended curative complex surgery for advanced cancer

“…Both departments were national treatment centers for CRS + HIPEC. At Department of Surgery, the procedure was offered as standard treatment, whereas the treatment was performed as a part of a clinical trial at Department of Gynecology [24].…”

Long-term follow-up of 46 cases of primary fallopian tube carcinoma: a single institute study

“…CRS followed by chemotherapy for the residual tumor has been recommended as a routine treatment of PFTC for decades (34). Several recent studies suggested that the platinum and paclitaxel-based chemotherapy regimen (TP) should be taken as the standard treatment in patients with PFTC (35).…”

Hyperthermic intraoperative thoracoabdominal chemotherapy for stage IVB epithelial ovarian carcinoma

“…Nephrotoxicity can also be an issue ( Dattatri et al, 2019 ). Carboplatin HIPEC has been demonstrated to be safe and effective in the treatment of EOC ( Mikkelsen et al, 2019 ) and was our agent of choice, as it reduces this risk compared to other agents such as cisplatin ( Colombo et al, 2016 ). Otherwise, few adjustments were made to the institution’s HIPEC protocol in order to perform HITAC.…”